相关实验视频

Updated: May 9, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

对IDH1抑制剂的专利审查 (2018年至今)

Qing Liang¹, Fei Wen¹, Peilin Wang¹

¹Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, China.

Expert opinion on therapeutic patents

|May 3, 2025

概括

突变异酸盐脱酶1 (mIDH1) 是一个有前途的癌症标. 最近的专利揭示了新的抑制剂和组合策略,以提高抗瘤疗效和克服耐药性.

科学领域:

生物化学生物化学
在瘤学瘤学.
药物发现药物发现药物发现

背景情况:

异酸脱酶1 (IDH1) 是TCA循环中的一个关键的代谢酶.
在各种癌症类型中,IDH1的突变很常见,这突出了其作为抗瘤点的潜力.
IDH1突变与许多癌症有关,使其成为治疗开发的重要焦点.

研究的目的:

审查关于抑制突变IDH1 (mIDH1) 的新分子,化合物,配方和方法的近期专利 (2018年至今).
探索增强抗瘤治疗疗效和减轻与mIDH1.1相关的耐药性的策略.
确定有希望的方法,包括组合疗法和双重/多重抑制剂,以准mIDH1.1.

主要方法:

从2018年到现在的专利的文献搜索.
从 Web of Science 和 PubMed 获取科学文献.
使用国家知识产权局的专利搜索和分析平台分析专利信息.
从Cortellis药物发现情报数据库中获取临床数据.

主要成果:

识别用于mIDH1抑制的新分子,化合物,配方和方法.
证据表明,涉及mIDH1抑制剂的组合疗法可以提高抗瘤疗效.
探索双重或多重抑制剂作为对抗mIDH1驱动癌症的潜在更有效策略.

结论:

针对mIDH1的单一疗法可能不足,因为固体瘤的复杂信号传递.
将mIDH1抑制剂与其他药物结合使用可以改善治疗结果并克服耐药性.
针对mIDH1的新型双重/多重抑制剂和功能分子代表了癌症治疗的有前途途途.

关键词:

一个IDH1一个IDH1 瘤这些瘤临床药物临床药物抑制剂抑制剂抑制剂代谢代谢代谢代谢新型化合物新型化合物

更多相关视频

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

相关概念视频

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...